Eric Joseph
Stock Analyst at JP Morgan
(1.36)
# 3,471
Out of 4,911 analysts
135
Total ratings
36.78%
Success rate
-10.53%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $45.74 | +39.92% | 4 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $4.21 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $3.14 | +1,301.27% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $7.47 | -6.29% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $44.70 | +49.89% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.37 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.57 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $11.54 | +160.08% | 7 | Jan 29, 2025 | |
| IGMS IGM Biosciences | Upgrades: Neutral | n/a | $1.27 | - | 8 | Jan 13, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $5.64 | +148.23% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $37.90 | +87.34% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $36.90 | +16.53% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $13.80 | +175.36% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $1.77 | +1,199.44% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $8.40 | +102.38% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $3.74 | +462.25% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $21.72 | +120.99% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $7.41 | +34.95% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.15 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.83 | +719.67% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.26 | +166.08% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $6.49 | +54.08% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $5.68 | +93.66% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $50.53 | -18.86% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $12.42 | +705.15% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.63 | +699.62% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.90 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $6.05 | +81.82% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.67 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $4.35 | +2,658.62% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $9.17 | +3,173.32% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.83 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $11.20 | +346.43% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $2.52 | +257.14% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.56 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.98 | +1,311.76% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $0.82 | +1,486.53% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.59 | +1,778.42% | 3 | Nov 14, 2018 |
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $45.74
Upside: +39.92%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.21
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $3.14
Upside: +1,301.27%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $7.47
Upside: -6.29%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $44.70
Upside: +49.89%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.37
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.57
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $11.54
Upside: +160.08%
IGM Biosciences
Jan 13, 2025
Upgrades: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.64
Upside: +148.23%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $37.90
Upside: +87.34%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $36.90
Upside: +16.53%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $13.80
Upside: +175.36%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $1.77
Upside: +1,199.44%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $8.40
Upside: +102.38%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $3.74
Upside: +462.25%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $21.72
Upside: +120.99%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $7.41
Upside: +34.95%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.15
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.83
Upside: +719.67%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.26
Upside: +166.08%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $6.49
Upside: +54.08%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $5.68
Upside: +93.66%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $50.53
Upside: -18.86%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $12.42
Upside: +705.15%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.63
Upside: +699.62%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.90
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $6.05
Upside: +81.82%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $8.67
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $4.35
Upside: +2,658.62%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $9.17
Upside: +3,173.32%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.83
Upside: -
Jul 12, 2021
Initiates: Neutral
Price Target: $50
Current: $11.20
Upside: +346.43%
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $2.52
Upside: +257.14%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.56
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.98
Upside: +1,311.76%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $0.82
Upside: +1,486.53%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.59
Upside: +1,778.42%